Symptomatology of irritable bowel syndrome and inflammatory bowel disease during the menstrual cycle

Gastroenterology Report

Volumn 3, Issue 3, 2015, Pages 185-193

  Bharadwaj, Shishira ^a   Barber, Matthew D ^a   Graff, Lesley A ^b   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Inflammatory bowel disease; Irritable bowel syndrome; Menstrual cycle; Symptomatology

Indexed keywords

EID: 84955097336     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gov010     Document Type: Review

References (90)

1. Rees WD and Rhodes J. Altered bowel habit and menstruation. Lancet 1976;2:475.
2. Simmons L, Heitkemper M and Shaver J. Gastrointestinal function during menstrual cycle. Health Care Women Int 1988; 9:201–9.
3. Wald A, Van Thiel DH, Hoechstetter L et al. Gastrointestinal transit: The effect of the menstrual cycle. Gastroenterology 1981;80:1497–500.
4. Daignault PG, Fazekas AG, Rosenthall L et al. Relationship between gall bladder contraction and progesterone receptors in patients with gallstones. Am J Surg 1988;155:147–51.
5. Richter JE. Review article: the management of heartburn in pregnancy. Aliment Pharmacol Ther 2005;22:749–57.
6. Kamm MA, Farthing MJ and Lennard-Jones JE. Bowel function and transit rate during the menstrual cycle. Gut. 1989;30: 605–8.
7. Hinds JP, Stoney B and Wald A. Does gender or the menstrual cycle affect colonic transit? Am J Gastroenterol 1989;84:123–26.
8. Heitkemper MM and Jarrett M. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology 1992;102:505–13.
9. Chan WY and Hill JC. Determination of menstrual prostaglandin levels in non-dysmenorrheic and dysmenorrheic subjects. Prostaglandins. 1978;15:365–75.
10. Palomba S, DiCello A, Riccio E, Manguso F, LaSala GB. Ovarian function and gastrointestinal motor activity. Minerva endo-crinologica. 2011;36:295–310.
11. Lim SM, Nam CM, Kim YN et al. The effect of the menstrual cycle on inflammatory bowel disease: a prospective study. Gut Liver 2013;7:51–7.
12. Mihm M, Gangooly S and Muttukrishna S. The normal menstrual cycle in women. Anim Reprod Sci 2011;124:229–36.
13. Bjornsson B, Orvar KB, Theodors A et al. The relationship of gastrointestinal symptoms and menstrual cycle phase in young healthy women. Laeknabladid 2006;92:677–82.
14. Moore J, Barlow D, Jewell D et al. Do gastrointestinal symptoms vary with menstrual cycle? Br J Obstet Gynaecol 1998;105: 1322–5.
15. Ganiban G, Besselman D, Harcelrode J et al. Effect of sex steroids on total gastrointestinal transit in male rats. Gastroenterology 1985;88:1713.
16. Davies GJ, Crowder M, Reid B et al. Bowel function measurements of individuals with different eating patterns. Gut 1986; 27:164–9.
17. Jung HK, Kim DY and Moon H. Effects of gender and menstrual cycle on colonic transit time in Healthy subjects. Korean J Intern Med 2003;18:181–6.
18. Bond EF, Heitkemper MM and Perigo R. Gastric emptying and gastric-intestinal transit in rats with varying ovarian hormone status. Nurs Res 1996;45:218–24.
19. Liu CY, Chen LB, Liu PY et al. Effects of progesterone on gastric emptying and intestinal transit in male rats. World J Gastroenterol 2002;8:338–41.
20. Ryan JR and Bhojwani A. Effect of ovariectomy and sex steroid hormone pretreatment on colonic transit in the rat. Gastroenterology 1985;88:156.
21. Heinemann A, Pieber D and Holzer P. Inhibition by female sex steroids of peristalsis in the guinea pig small intestine. Digestion 2002;65:213–19.
22. Diaz M, Ramirez CM, Marin R et al. Acute relaxation of mouse duodenum by estrogens. Evidence for an estrogen receptor independent modulation of muscle excitability. Eur J Pharmacol 2004;501:161–78.
23. Chen Q, Chitinavis V, Xiao Z et al. Impaired G protein function in gallbladder muscle from progesterone-treated guinea pigs. Am J Physiol 1998;274:283–9.
24. Martin VT, Lee J and Behbehani MM. Sensitization of the trigeminal sensory system during different stages of the rat estrous cycle: Implications for menstrual migraine. Headache 2007;47:552–63.
25. Dong XD, Mann MK, Kumar U et al. Sex-related differences in NMDA-evoked rat masseter muscle afferent discharge result from estrogen-mediated modulation of peripheral NMDA receptor activity. Neuroscience 2007;146:822–32.
26. Smith YR, Stohler CS, Nichols TE et al. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J Neurosci 2006;26:5777–85.
27. Bethea CL, Lu NZ, Gundlah C et al. Diverse actions of ovarian steroids in the serotonin neural system. Front Neuroendocrinol 2002;23:41–100.
28. Yildirir A, Kabakci G, Akgul E et al. Effects of menstrual cycle on cardiac autonomic innervation as assessed by heart rate variability. Ann Noninvasive Electrocardiol 2002;7:60–3.
29. Craft RM. Modulation of pain by estrogens. Pain 2007; 132(Suppl 1):S3–12.
30. Twyman RE and Macdonald RL. Neurosteroid regulation of GABAA receptor single-channel kinetic properties of mouse spinal cord neurons in culture. J Physiol 1992;456:215–45.
31. Rybaczyk LA, Bashaw MJ, Pathak DR et al. An overlooked connection: serotonergic mediation of estrogen-related physiology and pathology. BMC Womens Health 2005;5:12.
32. Zierau O, Zenclussen AC and Jensen F. Role of female sex hormones, estradiol and progesterone, in mast cell behavior. Front Immunol 2012;3:169.
33. Kirschbaum C, Kudielka BM, Gaab J et al. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitaryadrenal axis. Psychosom Med 1999;61:154–62.
34. Bradesi S, Eutamene H, Garcia-Villar R et al. Stress-induced visceral hypersensitivity in female rats is estrogen-dependent and involves tachykinin NK1 receptors. Pain 2003;102:227–34.
35. Dawood MY. Primary dysmenorrhea: Advances in pathogenesis and management. Obstet Gynecol 2006;108:428–41.
36. Occhipinti M. Prostaglandins and gastrointestinal function. Adv Pediatr 1978;25:205–21.
37. Sheibanie AF, Yen JH and Khayrullina T. The proinflamma-tory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23–>IL-17 axis. J Immunol 2007;178:8138–47.
38. Phiel KL, Henderson RA, Adelman SJ et al. Differential estrogen receptor gene expression in human peripheral blood mononuclear cell populations. Immunol Lett 2005;97:107–113.
39. Nilsson BO. Modulation of the inflammatory response by estrogens with focus on the endothelium and its interactions with leukocytes. Inflamm Res 2007:56:269–73.
40. Turnbull GK, Thompson DG, Day S et al. Relationships between symptoms, menstrual cycle and orocecal transit in normal and constipated women. Gut 1989;30:30–4.
41. Bovo P, Brunori MP, Francesco VD et al. The menstrual cycle has no effect on gastrointestinal transit time. Evaluation by means of lactose hydrogen breath test. Ital J Gastroenterol 1992;2:449–51.
42. Degen LP and Phillips SF. Variability of gastrointestinal transit in healthy women and men. Gut 1996;39:299–305.
43. Heitkemper MM, Chang L. Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome? Gend Med 2009;6:152–67.
44. Payne S. Sex, gender, and irritable bowel syndrome: making the connections. Gend Med 2004;1:18–28.
45. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders. Gastroenterology 2006;130:1480–91.
46. Drossman DA and Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009–16.
47. Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770–98.
48. Talley NJ. Serotoninergic neuroenteric modulators. Lancet 2001;358:2061–8.
49. Houghton LA, Lea R, Jackson N et al. The menstrual cycle affects rectal sensitivity in patients with irritable bowel syndrome but not healthy volunteers. Gut 2002;50:471–4.
50. Whitehead WE, Cheskin LJ, Heller BR et al. Evidence for exacerbation of irritable bowel syndrome during menses. Gastroenterology. 1990;98:1485–9.
51. Heitkemper M, Jarrett M, Cain KC et al. Daily gastrointestinal symptoms in women with and without a diagnosis of IBS. Dig Dis Sci 1995;40:1511–19.
52. Kane SV, Sable K and Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence Study. Am J Gastroenterol 1998;93: 1867–72.
53. Lee Y, Mayer EA, Schmulson M et al. Gender related symptoms in IBS symptoms. Am J Gastroenterol 2001;96:2185–93.
54. Heitkemper MM, Cain KC, Jarrett ME et al. Symptoms across the menstrual cycle in women with IBS. Am J Gastroenterol 2003;98:420–30.
55. Lee SY, Kim JH, Sung IK et al. Irritable bowel syndrome is more common in women regardless of the menstrual phase: a Rome II-based survey. J Korean Med Sci 2007;22:851–4.
56. Houghton LA, Perry H, Morris J et al. Plasma 5-hydroxytrypta-mine concentration varies with gender and menstrual status in irritable bowel syndrome patients with diarrhea (IBS-D) but not healthy volunteers. Gastroenterology 2008;134(Suppl 1):A681.
57. Beglinger C. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome. Int J Clin Pract 2002; 56:47–51.
58. Koch KM, Palmer JL, Noordin N et al. Sex and age differences in the pharmacokinetics of alosetron. Br J Clin Pharmacol 2002; 53:238–42.
59. Palsson OS, Turner MJ, van Tilburg MAL et al. Survey of the effects of changes in female sex hormones on irritable bowel syndrome. Gastroenterology 2003;124(Suppl 1):A396.
60. Adeyemo MA, Spiegel BM and Chang L. Meta-analysis: Do irritable bowel syndrome symptoms vary between men and women. Aliment Pharmacol Ther 2010;32:738–55.
61. Ruigómez A, García Rodríguez LA, Johansson S et al. Is hormone replacement therapy associated with an increased risk of irritable bowel syndrome? Maturitas 2003;44:133–40.
62. Parlak E, Dagli U and Alkim C. Pattern of gastrointestinal and psychosomatic symptoms across the menstrual cycle in women with inflammatory bowel disease. Turk J Gastroenterol 2003;13:250–6.
63. Bernstein MT, Graff LA and Targownik LE. Gastrointestinal symptoms before and during menses in women with IBD. Aliment Pharmacol Ther 2012;36:135–44.
64. Lichtarowicz A, Norman C, Calcraft B et al. A study of the menopause, smoking, and contraception in women with Crohn’s disease. Q J Med 1989;72:623–31.
65. Kane SV and Reddy D. Hormonal replacement therapy after menopause is protective of disease activity in women with inflammatory bowel disease. Am J Gastroenterol 2008;103: 1193–6.
66. Bharadwaj S, Wu XR, Barber MD et al. Association between gastrointestinal symptoms and menstruation in patients with ileal pouches. Gastroenterol Rep (Oxf);2:207–14.
67. Cornish JA, Tan E, Simillis C et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol 2008;103:2394–400.
68. Zapata LB, Paulen ME, Cansino C et al. Contraceptive use among women with inflammatory bowel disease: A systematic review. Contraception 2010;82:72–85.
69. Cosnes J, Carbonnel F, Carrat F et al. Oral contraceptive use and the clinical course of Crohn’s disease: a prospective cohort study. Gut 1999;45:218–22.
70. Okoro NI and Kane SV. Gender related issues in the female inflammatory bowel disease patient. Expert Rev Gastroenterol Hepatol 2009;3:145–54.
71. Moleski SM and Choudhary C. Special considerations for women with IBD. Gastroenterol Clin N Am 2011;40:387–98.
72. Marri SR, Ahn C and Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:591–9.
73. Marjoribanks J, Proctor M, Farquhar C et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev 2010;(1):CD001751.
74. Edlow AG and Bartz D. Hormonal Contraceptive Options for Women With Headache: A Review of the Evidence. Rev Obstet Gynecol 2010;3:55–65.
75. Nilsson LO, Victor A, Kral JG et al. Absorption of an oral contraceptive gestagen in ulcerative colitis before and after proctocolectomy and construction of a continent ileostomy. Contraception 1985;31:195–204.
76. Bernstein CN, Leslie WD and Leboff M. AGA technical review: osteoporosis in gastrointestinal disease. Gastroenterology 2003;124:795–841.
77. Jamieson DJ and Steege JF. The prevalence of dysmenorrhea, dyspareunia, pelvic pain, and irritable bowel syndrome in primary care practices. Obstet Gynecol 1996;87:55–8.
78. Altman G, Cain KC, Motzer S et al. Increased symptoms in female IBS patients with dysmenorrhea and PMS. Gastroenterol Nurs 2006;29:4–11.
79. Saha S, Midtling E, Roberson E et al. Dysmenorrhea in women with Crohn’s disease: a case-control study. Inflamm Bowel Dis 2013;19:1463–9.
80. Lea R, Bancroft K and Whorwell PJ. Irritable bowel syndrome, chronic pelvic inflammatory disease and endometriosis: A comparison of symptomatology. Eur J Gastroenterol Hepatol 2004;16:1269–72.
81. Seaman HE, Ballard KD, Wright JT et al. Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study–Part 2. BJOG 2008;115:1392–6.
82. Jess T, Frisch M, Jørgensen KT et al. Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study. Gut 2012;61:1279–83.
83. Mathur R, Ko A, Hwang LJ et al. Polycystic ovary syndrome is associated with an increased prevalence of irritable bowel syndrome. Dig Dis Sci 2010;55:1085–9.
84. Singh S, Graff LA and Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol 2009;104:1298–313.
85. Tang LY, Nabalamba A, Graff LA et al. A comparison of self-perceived health status in inflammatory bowel disease and irritable bowel syndrome patients from a Canadian national population survey. Can J Gastroenterol 2008;22:475–83.
86. Graff LA, Walker JR and Bernstein CN. It’s not just about the gut: managing depression and anxiety in inflammatory bowel disease. Pract Gastroenterol 2010;62:11–25.
87. Ford AC, Talley NJ, Schoenfeld PS et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58:367–78.
88. Mikocka-Walus AA, Turnbull DA, Moulding NT et al. Antidepressants and inflammatory bowel disease: a systematic review. Clin Pract Epidemiol Ment Health 2006; 2:24.
89. Keefer L, Kiebles JL, Martinovich Z et al. Behavioral interventions may prolong remission in patients with inflammatory bowel disease. Behav Res Ther 2011;49:145–50.
90. McCombie AM, Mulder RT and Gearry RB. Psychotherapy for inflammatory bowel disease: a review and update. J Crohns Colitis 2013;7:935–49.